Heidelberg Pharma to Showcase ADC Technology at AACR 2026

Heidelberg Pharma AG, a biotech firm at the clinical stage, is set to present its promising findings at the upcoming AACR Annual Meeting in San Diego. The company will unveil the preclinical data on HDP-103, an Amanitin-based Antibody Drug Conjugate (ADC) aimed at tackling metastatic castration-resistant prostate cancer (mCRPC).

The poster presentation will focus on the efficacy of HDP-103 even in complex patient-derived xenograft models. The Amanitin-based ADC has shown superior performance in comparison to traditional treatments and comes with a manageable safety profile observed during trials with non-human primates. Key effects were confined to expected reactions mainly affecting the liver and kidney.

The unique action mechanism of HDP-103 gives it an edge over current mCRPC treatments, indicating significant potential for future clinical development. This advance fulfils a crucial need for patients with del(17p), displaying robust antitumor activity with a favorable therapeutic index.